NVCTNuvectis Pharma, Inc.
$20.13+229% 1Y
$20.13
$5.6552 weeks$28.52
Price
+229%1YEnd-of-day closes, not the intraday tick.
RyuScore
Weak, higher than 6% of companiesThe five questions
2 of 5 availableOnly two of the five can be answered for NVCT today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.
- Is the business good?not enough filed
- Is it safe?Watch
- Is the price fair?not enough filed
- Is it growing?not enough filed
- What is the market doing?Mixed
P/En/a
Market value$534.0M
1 year+229%
5 yearsn/a
Charts
As reported to the SEC, without any scoring.
The next results filing is expected around Nov 3, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 21, 2026Establishment of “At the Market” Offering Program On August 21, 2026, Nuvectis Pharma, Inc., a Delaware corporation (the “Company”), entered into an Open Market Sale Agreement SM (the “Sale Agreement”) with Jefferies LLC (“Jefferies”) as sales agent, pursuant to which the Company may offer and sell shares (the “ATM …Other event · Form 8-K
- Aug 4, 2026Nuvectis Pharma Reports Second Quarter.Earnings release · press release
- Jun 30, 2026On June 29, 2026, Nuvectis Pharma, Inc. (“Nuvectis” or the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. (the “Representative”)Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.